Pacira BioSciences (PCRX) Cash from Financing Activities (2010 - 2026)

Pacira BioSciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$59.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 1883.9% year-over-year to -$59.4 million in Q1 2026; TTM through Mar 2026 was -$426.0 million, a 2578.94% decrease from a year earlier, with the FY2025 full-year figure at -$369.6 million, down 2228.82% from the prior year.
• Cash from Financing Activities slipped to -$59.4 million in Q1 2026 per PCRX's latest filing, from -$51.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $25.0 million in Q2 2024 and bottomed at -$257.5 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is -$27.8 million (2023), against an average of -$58.6 million.
• Across the five-year window, Cash from Financing Activities soared 5577.27% in 2024 and tumbled 8950.12% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$58.5 million in 2022, then soared by 96.96% to -$1.8 million in 2023, then declined by 9.89% to -$2.0 million in 2024, then sank by 2542.05% to -$51.7 million in 2025, then fell by 15.0% to -$59.4 million in 2026.
• Per Business Quant, the three latest PCRX Cash from Financing Activities figures stand at -$59.4 million (Q1 2026), -$51.7 million (Q4 2025), and -$257.5 million (Q3 2025).